The objectives of this study are to assess PMNL function in HIV+ patients at different stages of disease over an extended period of time, determine if abnormal PMNL function predisposes patients to bacterial infections, and examine the various factors that may affect PMNL function. In addition, we will examine whether or not defects in PMNL function can be reversed by in vitro exposure to colony-stimulating factors. METHODS: Subjects. HIV-infected patients will be grouped according to CD4+ counts (> 500/mm3, 200-500/mm3, and < 200/mm3) and whether or not they are receiving anti-retroviral therapy. Controls groups will consist of patients at risk for HIV infection with a negative HIV antibody test and healthy volunteers without risk factor for HIV infection. Clinical data, including age, risk factors for HIV infection, staging (CDC, Walter Reed), and the occurrence of bacterial infections will be recorded. PMNL function. PMNLs will be isolated from patients and controls and a battery of function assays performed. Chemotaxis, adherence, aggregation, superoxide production in response to stimuli (f-met-leu-phe, PMA, and opsonized zymosan) in a superoxide dismutase (SOD) inhibitable cytochrome C reduction microassay, phagocytosis, and bacterial killing will be determined for patients and compared to the paired control. Effect of colony-stimulating factors on PMNL function. PMNLs will be preincubated with granulocyte and granulocyte-macrophage colony-stimulating factors (G-CSF, GM-CSF) and tested with the battery of assays described above. Factors associated with abnormal PMNL function. We plan to measure circulating levels of immunoglobulins, fibronectin, PMNL chemoattractants (C5a, leukotriene B4, and platelet activating factor), cytokines that affect PMNL function (TNF, IL-1, and gamma-interferon), and colony- stimulating factors, and correlate levels with PMNL function. Fluorocytometry will be used to detect anti-neutrophil antibodies and the expression of PMNL surface markers that are associated with normal PMNL function. Methods of Analysis. The results of PMNL function tests will be reported as the mean plus/minus standard deviation. The means of groups will be analyzed by the Student's test and ANOVA. The relationship between stage of disease and PMNL function will be analyzed by linear regression and ANOVA. Associations between bacterial infections and PMNL function, anti- retroviral therapy, circulating factors, anti-retroviral therapy, circulating factors, anti-PMNL antibodies, surface markers, and other parameters will be analyzed by multivariate analysis.

Project Start
1997-01-01
Project End
1997-12-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
11
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Kelesidis, Theodoros; Tran, Thuy Tien T; Stein, James H et al. (2015) Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis 61:651-60
Safren, Steven A; Biello, Katie B; Smeaton, Laura et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One 9:e104178
Sacktor, Ned; Miyahara, Sachiko; Evans, Scott et al. (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620-6
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Safren, Steven A; Hendriksen, Ellen S; Smeaton, Laura et al. (2012) Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS Behav 16:266-77
Chaplin, B; Eisen, G; Idoko, J et al. (2011) Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. AIDS Res Hum Retroviruses 27:71-80
Grinsztejn, Beatriz; Smeaton, Laura; Barnett, Ronald et al. (2011) Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther 16:1057-62
Grady, Benjamin J; Torstenson, Eric S; McLaren, Paul J et al. (2011) Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac Symp Biocomput :253-64
Cohn, Susan E; Jiang, Hongyu; McCutchan, J Allen et al. (2011) Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care 23:775-85
Sacktor, N; Miyahara, S; Deng, L et al. (2011) Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 77:1135-42

Showing the most recent 10 out of 87 publications